Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

For people with a certain sleep disorder, a simple blood test could help predict the development of dementia years before ...

Mar. 9, 2025 — A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells ...

Mar. 9, 2025 — A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells ...

The research findings primarily focus on individuals with a sleep disorder but may have broader implications. A recent study ...

Teleneurorehabilitation provides similar improvement in motor and nonmotor symptoms for patients with Parkinson’s disease as ...

Parkinson’s can cause a condition called Parkinson’s disease dementia. This condition is marked by a decline in thinking, reasoning, and problem-solving. Parkinson’s disease is a progressive ...

Stay informed with Hindustan Times' live updates! Track the latest lifestyle news including fashion trends, style guide & ...

Researchers at McGill University found that a blood test originally designed for Alzheimer’s can predict dementia risk in ...

Gain Therapeutics (GANX) announced the dosing of the first participant with Parkinson’s disease in its Phase 1b clinical trial of GT-02287, the ...